Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
Abstract Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting inhibitory and stimulatory pathways of immune cells like T cells and dendritic cells (DC). The investigation into the combin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-09-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-023-02083-y |
| _version_ | 1797451646592090112 |
|---|---|
| author | Seyed Hossein Kiaie Hossein Salehi-Shadkami Mohammad Javad Sanaei Marzieh Azizi Mahdieh Shokrollahi Barough Mohammad Sadegh Nasr Mohammad Sheibani |
| author_facet | Seyed Hossein Kiaie Hossein Salehi-Shadkami Mohammad Javad Sanaei Marzieh Azizi Mahdieh Shokrollahi Barough Mohammad Sadegh Nasr Mohammad Sheibani |
| author_sort | Seyed Hossein Kiaie |
| collection | DOAJ |
| description | Abstract Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting inhibitory and stimulatory pathways of immune cells like T cells and dendritic cells (DC). The investigation into the combination therapies through novel immune checkpoint inhibitors (ICIs) has been limited due to immune-related adverse events (irAEs), low response rate, and lack of optimal strategy for combinatorial cancer immunotherapy (IMT). Nanoparticles (NPs) have emerged as powerful tools to promote multidisciplinary cooperation. The feasibility and efficacy of targeted delivery of ICIs using NPs overcome the primary barrier, improve therapeutic efficacy, and provide a rationale for more clinical investigations. Likewise, NPs can conjugate or encapsulate ICIs, including antibodies, RNAs, and small molecule inhibitors. Therefore, combining the drug delivery system (DDS) with ICP therapy could provide a profitable immunotherapeutic strategy for cancer treatment. This article reviews the significant NPs with controlled DDS using current data from clinical and pre-clinical trials on mono- and combination IMT to overcome ICP therapeutic limitations. Graphical Abstract |
| first_indexed | 2024-03-09T14:57:29Z |
| format | Article |
| id | doaj.art-c690d1ff8ad14886be4ad9c870a81307 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-03-09T14:57:29Z |
| publishDate | 2023-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-c690d1ff8ad14886be4ad9c870a813072023-11-26T14:08:00ZengBMCJournal of Nanobiotechnology1477-31552023-09-0121111810.1186/s12951-023-02083-yNano-immunotherapy: overcoming delivery challenge of immune checkpoint therapySeyed Hossein Kiaie0Hossein Salehi-Shadkami1Mohammad Javad Sanaei2Marzieh Azizi3Mahdieh Shokrollahi Barough4Mohammad Sadegh Nasr5Mohammad Sheibani6Department of Formulation Development, ReNAP TherapeuticsDepartment of Formulation Development, ReNAP TherapeuticsCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical SciencesInstitute of Biochemistry and Biophysics (IBB), University of TehranDepartment of Immunology, School of Medicine, Iran University of Medical SciencesDepartment of Computer Science and Engineering Multi-Interprofessional Center for Health Informatics (MICHI), The University of Texas at ArlingtonDepartment of Pharmacology, School of Medicine, Iran University of Medical SciencesAbstract Immune checkpoint (ICP) molecules expressed on tumor cells can suppress immune responses against tumors. ICP therapy promotes anti-tumor immune responses by targeting inhibitory and stimulatory pathways of immune cells like T cells and dendritic cells (DC). The investigation into the combination therapies through novel immune checkpoint inhibitors (ICIs) has been limited due to immune-related adverse events (irAEs), low response rate, and lack of optimal strategy for combinatorial cancer immunotherapy (IMT). Nanoparticles (NPs) have emerged as powerful tools to promote multidisciplinary cooperation. The feasibility and efficacy of targeted delivery of ICIs using NPs overcome the primary barrier, improve therapeutic efficacy, and provide a rationale for more clinical investigations. Likewise, NPs can conjugate or encapsulate ICIs, including antibodies, RNAs, and small molecule inhibitors. Therefore, combining the drug delivery system (DDS) with ICP therapy could provide a profitable immunotherapeutic strategy for cancer treatment. This article reviews the significant NPs with controlled DDS using current data from clinical and pre-clinical trials on mono- and combination IMT to overcome ICP therapeutic limitations. Graphical Abstracthttps://doi.org/10.1186/s12951-023-02083-yImmune checkpointNanoparticlesChemoimmunotherapyPD-1 and PD-L1CTLA-4Tumor microenvironment |
| spellingShingle | Seyed Hossein Kiaie Hossein Salehi-Shadkami Mohammad Javad Sanaei Marzieh Azizi Mahdieh Shokrollahi Barough Mohammad Sadegh Nasr Mohammad Sheibani Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy Journal of Nanobiotechnology Immune checkpoint Nanoparticles Chemoimmunotherapy PD-1 and PD-L1 CTLA-4 Tumor microenvironment |
| title | Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy |
| title_full | Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy |
| title_fullStr | Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy |
| title_full_unstemmed | Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy |
| title_short | Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy |
| title_sort | nano immunotherapy overcoming delivery challenge of immune checkpoint therapy |
| topic | Immune checkpoint Nanoparticles Chemoimmunotherapy PD-1 and PD-L1 CTLA-4 Tumor microenvironment |
| url | https://doi.org/10.1186/s12951-023-02083-y |
| work_keys_str_mv | AT seyedhosseinkiaie nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy AT hosseinsalehishadkami nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy AT mohammadjavadsanaei nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy AT marziehazizi nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy AT mahdiehshokrollahibarough nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy AT mohammadsadeghnasr nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy AT mohammadsheibani nanoimmunotherapyovercomingdeliverychallengeofimmunecheckpointtherapy |